Aptose Biosciences (APTO)
(Delayed Data from NSDQ)
$0.36 USD
0.00 (1.19%)
Updated Oct 18, 2024 03:53 PM ET
After-Market: $0.38 +0.02 (4.31%) 6:06 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.36 USD
0.00 (1.19%)
Updated Oct 18, 2024 03:53 PM ET
After-Market: $0.38 +0.02 (4.31%) 6:06 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
What's in Store for Conatus (CNAT) This Earnings Season?
by Zacks Equity Research
Conatus' (CNAT) progress with lead candidate emricasan might boost the stock in Q4. However, the company's portfolio lacks an approved product and its revenue generation.
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
Investors focus will be on pipeline and regulatory updates during Catalyst's (CPRX) fourth-quarter earnings call.
What's in the Cards for BioDelivery (BDSI) in Q4 Earnings?
by Zacks Equity Research
BioDelivery's (BDSI) lead drugs Belbuca and Bunavail look promising to deliver an earnings beat in Q4.
Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Madrigal (MDGL) has no approved product in its portfolio. So, investors' complete focus on fourth-quarter earnings call will be revolving around the company's lead pipeline candidate, MGL-3196.
What's in the Cards for Puma (PBYI) This Earnings Season?
by Zacks Equity Research
Contrary to nominal sales generated by Puma's (PBYI) only marketed drug Nerlynx last quarter, post its launch in August 2017, the candidate is likely to fetch higher revenues in Q4.
The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals
4 Top-Ranked Biotech Stocks Under $20 With Room for Growth
by Zacks Equity Research
We take a look at the biotech stocks with a potential for growth keeping in mind that the industry has witnessed a rebound in 2017 from last year's challenges.